Cited 84 time in
Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yoon, Yeong Sook | - |
| dc.contributor.author | Kwon, A. Rom | - |
| dc.contributor.author | Lee, Yoon Kyung | - |
| dc.contributor.author | Oh, Sang Woo | - |
| dc.date.accessioned | 2023-04-28T03:40:51Z | - |
| dc.date.available | 2023-04-28T03:40:51Z | - |
| dc.date.issued | 2019-07 | - |
| dc.identifier.issn | 1871-403X | - |
| dc.identifier.issn | 1878-0318 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/7935 | - |
| dc.description.abstract | Background: Obesity can influence on carcinogenesis through alterations in adipokines and subsequent inflammatory changes. This meta-analysis was aimed to comprehensively assess the association between circulating adipokines and risk of obesity-related cancers. Methods: Pubmed and Embase were searched up to October 2017 for observational studies investigating the relationship between adipokines and cancers. Pooled odds ratio and the corresponding 95% confidence interval was estimated through the meta-analysis using a random-effects model. Findings A total of 93 observational studies (adiponectin = 60, high molecular weight adiponectin = 9, leptin = 39, IL-6 = 16, TNF-alpha = 10, and resistin = 17) were included. Adiponectin was significantly associated with decreased risk of cancer (pooled OR 0.70, 95% CI 0.60-0.80; I-2 = 71.9%; P-heterogeneity < 0.01). Leptin was significantly associated with increased risk of cancer (1.26, 1.05-1.51; I-2 = 65.7%; P-heterogeneity < 0.01). For each 5 mu g/ml increase in adiponectin and 5 ng/ml increase in leptin, the pooled OR was 0.88 (0.83-0.93; I-2 = 80.2%; P-heterogeneity < 0.01) and 1.05 (1.01-1.09; I-2 = 67.9%; P-heterogeneity < 0.01)), respectively. There was nonlinear dose-response association (P-nonlinearity for adiponectin = 0.01; P-nonlinearity for leptin = 0.003). IL-6 (1.09, 0.94-1.25), TNF-alpha (1.65, 0.99-2.74), and resistin (1.28, 0.78-2.11) was not associated with risk of cancer. By cancer site and type, highest category of adiponectin was associated with decreased risk of breast (OR 0.74, 0.60-0.91), colorectal (0.74, 0.60-0.91), and endometrial cancer (0.49, 0.34-0.72). Higher leptin was associated with increased risk of endometrial (1.88, 1.24-2.87) and kidney cancer (2.07, 1.51-2.83). Conclusion: Our study suggests that adiponectin and leptin may play a role in the etiology of cancer. (C) 2019 Published by Elsevier Ltd on behalf of Asia Oceania Association for the Study of Obesity. | - |
| dc.format.extent | 11 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | ELSEVIER SCI LTD | - |
| dc.title | Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.orcp.2019.03.006 | - |
| dc.identifier.scopusid | 2-s2.0-85064260997 | - |
| dc.identifier.wosid | 000480688600001 | - |
| dc.identifier.bibliographicCitation | OBESITY RESEARCH & CLINICAL PRACTICE, v.13, no.4, pp 329 - 339 | - |
| dc.citation.title | OBESITY RESEARCH & CLINICAL PRACTICE | - |
| dc.citation.volume | 13 | - |
| dc.citation.number | 4 | - |
| dc.citation.startPage | 329 | - |
| dc.citation.endPage | 339 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
| dc.relation.journalResearchArea | Nutrition & Dietetics | - |
| dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
| dc.relation.journalWebOfScienceCategory | Nutrition & Dietetics | - |
| dc.subject.keywordPlus | MOLECULAR-WEIGHT ADIPONECTIN | - |
| dc.subject.keywordPlus | C-REACTIVE PROTEIN | - |
| dc.subject.keywordPlus | RENAL-CELL CARCINOMA | - |
| dc.subject.keywordPlus | SOLUBLE LEPTIN RECEPTOR | - |
| dc.subject.keywordPlus | MULTIPLE-MYELOMA RISK | - |
| dc.subject.keywordPlus | COLORECTAL-CANCER | - |
| dc.subject.keywordPlus | BREAST-CANCER | - |
| dc.subject.keywordPlus | ENDOMETRIAL CANCER | - |
| dc.subject.keywordPlus | PLASMA ADIPONECTIN | - |
| dc.subject.keywordPlus | SERUM ADIPONECTIN | - |
| dc.subject.keywordAuthor | Obesity | - |
| dc.subject.keywordAuthor | Cancer | - |
| dc.subject.keywordAuthor | Adipokine | - |
| dc.subject.keywordAuthor | Inflammation | - |
| dc.subject.keywordAuthor | Meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
